Journey Medical Corporation · NASDAQ:DERM
Journey Medical — Corporate Update (February 2025)
36 slides from Journey Medical's corporate update, Feb 5, 2025
Slide 1: Emrosi – U.S. Commercial Plan Conference Call
1 | © 2025 Journey Medical Corporation. All rights reserved. EMROSI – U.S. COMMERCIAL PLAN CONFERENCE CALL February 5, 2025
Slide 2: Forward-Looking Statements
2 | © 2025 Journey Medical Corporation. All rights reserved. FORWARD - LOOKING STATEMENTS FORWARD - LOOKING STATEMENTS This press release may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Slide 3: Speakers & Agenda
3 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Claude Maraoui Founder, President & Chief Executive Officer • Emrosi – Differentiated Clinical Profile • Market Opportunity • Commercial Strategy • Market Access • Financial Update • Closing Remarks
Slide 4: Emrosi Commercial Highlights
4 | © 2025 Journey Medical Corporation. All rights reserved. Emrosi Commercial Highlights • Emrosi received FDA - Approved in November 2024; On time, First - cycle review • Superior to both placebo and market - leading oral rosacea treatment, Oracea ® • 16.5 million Americans suffer from rosacea 1 •
Slide 5: Today's Speakers
5 | © 2025 Journey Medical Corporation. All rights reserved. Today’s Speakers Brian Prout Executive Director, Marketing Claude Maraoui Founder, President & CEO Joseph Benesch Chief Financial Officer Srinivas Sidgiddi, M.D. Vice President, R&D Louis Donati Director, Market Access Andrew Zwible Vice P
Slide 6: Speakers & Agenda
6 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Srinivas Sidgiddi, M.D, Vice President, Research & Development • Commercial Highlights • Market Opportunity • Commercial Strategy • Market Access • Financial Update • Closing Remarks
Slide 7: Rosacea Affects ~16.5mm Americans and Can Have Debilitating Effects
7 | © 2025 Journey Medical Corporation. All rights reserved. Rosacea Affects ~16.5mm Americans 1 and Can Have Debilitating Effects on Quality of Life • Rosacea is a chronic, relapsing, inflammatory skin condition with symptoms such as acne - like inflammatory lesions (papules and pustules), deep fac
Slide 8: Emrosi – A Novel Minocycline Formulation
8 | © 2025 Journey Medical Corporation. All rights reserved. • Minocycline in Emrosi is 25% IR & 75% ER compared to doxycycline in Oracea that is 75% IR & 25% ER. • Minocycline has a lower Cmax and levels in the blood throughout the day compared to doxycycline at the same dose. • Blood is not the si
Slide 9: Emrosi – Indication & Dosage
9 | © 2025 Journey Medical Corporation. All rights reserved. Emrosi – Indication & Dosage Once daily dose, any time of day, with or without food Lowest approved oral minocycline dose (much lower than the approved antibiotic doses) Fixed dose independent of body weight Label contains head - to - head
Slide 10: Emrosi Demonstrated Superior Efficacy Over Oracea and Placebo
10 | © 2025 Journey Medical Corporation. All rights reserved. 62.7 39 28.2 Emrosi (40mg) N=245 Oracea (40mg) N=246 Placebo N=162 % of Subjects • Pooled results from the two phase 3 studies demonstrate outstanding efficacy for Emrosi. • Significantly superior to Oracea and Placebo on all efficacy par
Slide 11: Emrosi Demonstrated A Safety Profile Similar to Placebo
11 | © 2025 Journey Medical Corporation. All rights reserved. Key Treatment - Related Adverse Events (N=638) 2.1% 2.1% 1.6% 0.8% 0.0% 3.4% 2.1% 0.8% 1.3% 2.1% 2.5% 3.8% 0.0% 1.3% 1.3% 0% 2% 4% 6% 8% 10% 12% 14% Headache Diarrhea Dyspepsia Gastroesophageal Reflux Nausea % of Patients Emrosi (Minocycl
Slide 12: Emrosi – Publication & Data Communication Plan
12 | © 2025 Journey Medical Corporation. All rights reserved. • Three manuscript submissions are in process at leading peer - reviewed journals, covering the following topics: • Safety & Efficacy vs. Placebo & Oracea for Lesions & Erythema • Microbiology • Quality of Life Improvement • Clinical post
Slide 13: Speakers & Agenda
13 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Andrew Zwible Vice President, Operations • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Commercial Strategy • Market Access • Financial Update • Closing Remarks
Slide 14: Estimated U.S. Rosacea Patients (2023)
14 | © 2025 Journey Medical Corporation. All rights reserved. ESTIMATED U.S. ROSACEA PATIENTS (2023) It is estimated that only 2 - 3 million Americans with rosacea are receiving treatment 1 , and millions of additional patients with rosacea may be in temporary remission Patient From Emrosi Phase 3 T
Slide 15: Large and Growing Market: ~5.1mm TRXs Filled in 2024
15 | © 2025 Journey Medical Corporation. All rights reserved. Large and Growing Market: ~5.1mm TRXs Filled in 2024 TOPICAL ROSACEA TREATMENTS: Currently available topical rosacea treatments are only indicated for one of the rosacea features below: • Erythema • Papules & Pustules Azelex (Azelaic Acid
Slide 16: Over 712k Prescriptions for Oral Rosacea Treatments Alone in 2024
16 | © 2025 Journey Medical Corporation. All rights reserved. Over 712k Prescriptions for Oral Rosacea Treatments Alone in 2024 ORACEA OVERVIEW Oracea (doxycycline 40mg) wa s the first and only FDA approved oral medication for Rosacea before Emrosi Indication: Treatment of only inflammatory lesions
Slide 17: Journey Sales Force Can Cover Vast Majority of Oral Rosacea Prescriptions
17 | © 2025 Journey Medical Corporation. All rights reserved. Source: IQVIA Prescriber - level Data TRx = Total number of prescriptions 94% of Oral Rosacea TRx are written in Dermatology (based on IQVIA 2024 TRx) 83% of Oral Rosacea Derm TRx will be covered at launch (based on IQVIA 2024 TRx) Journe
Slide 18: Journey Can Reach 80% of TRx With Bi-weekly Call Frequency
18 | © 2025 Journey Medical Corporation. All rights reserved. Journey Can Reach 80% of TRx Written With Optimal Bi - weekly Call Frequency Source: IQVIA Prescriber - level Data TRx = Total number of prescriptions HCPs • 547k Oral Rosacea TRx in Journey territories in 2024 (IQVIA prescriber - level d
Slide 19: Speakers & Agenda
19 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Robert Nevin Chief Commercial Officer • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Market Opportunity • Market Access • Financial Update • Closing Remarks
Slide 20: Oracea Launch Attained Over 90K TRx in Launch Year
20 | © 2025 Journey Medical Corporation. All rights reserved. • Oracea Launched in July 2006 • Over 700K TRx by Year 5 • Peak TRx of 769K in 2012 Source: Symphony Healthcare Metys Data Oracea Launch Oracea Attained Over 90K TRx in Its Launch Year and Continued To Grow, Peaking in 2012 At 770K - 100,
Slide 21: Trends in Dermatology Are Favorable to the Growth of Emrosi
21 | © 2025 Journey Medical Corporation. All rights reserved. Source: Barbieri JS, Bhate K, Hartnett KP, Fleming - Dutra KE, Margolis DJ. Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016. JAMA Dermatol. 2019 Mar 1;155(3):290 - 297. doi : 10.1001/jamadermatol.2018.4944. PMID: 30649
Slide 22: Pillars to Driving Dermatologist Adoption of Emrosi
22 | © 2025 Journey Medical Corporation. All rights reserved. 4 Pillars to Driving Dermatologist Adoption of Emrosi Simplify Refill Adherence Enable Patient Access Build HCP Awareness Direct Promotion • Enhance refill visibility at the pharmacy • Direct messaging to patients to support refill adhere
Slide 23: Dermatology Provider's Perceptions of Emrosi
23 | © 2025 Journey Medical Corporation. All rights reserved. Dermatology Provider’s Perceptions of Emrosi 74% of HCPs are “Very Likely” to prescribe Emrosi 70% of HCPs perceive Emrosi to be “Extremely Valuable ” 40% of HCPs report a “very high therapeutic unmet need” in the treatment of rosacea Bas
Slide 24: Speakers & Agenda
24 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Brian Prout Executive Director of Marketing • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Market Opportunity • Market Access • Financial Update • Closing Remarks
Slide 25: Emrosi Has a Unique Mix of Patient Benefits
25 | © 2025 Journey Medical Corporation. All rights reserved. EMROSI is the best - in - class oral therapy for inflammatory lesions of rosacea and is expected to become the new standard of care in rosacea therapy ACCESS & SAVINGS CONVENIENCE UNIQUENESS SAFETY EFFICACY Nationwide access Simplified pa
Slide 26: Examples of Emrosi HCP Visual Sales Aid
26 | © 2025 Journey Medical Corporation. All rights reserved. Examples of Emrosi HCP Visual Sales Aid
Slide 27: Patient Results At Baseline & Weeks Post Treatment
27 | © 2025 Journey Medical Corporation. All rights reserved. Patient Results At Baseline & 16 Weeks Post Treatment Actual patient images from Emrosi Phase 3 Clinical Trials. Photos used with permission. Results of individual patients may not be typical, as individual results may vary.
Slide 28: Patient Results At Baseline & Weeks Post Treatment
28 | © 2025 Journey Medical Corporation. All rights reserved. Patient Results At Baseline & 16 Weeks Post Treatment Actual patient images from Emrosi Phase 3 Clinical Trials. Photos used with permission. Results of individual patients may not be typical, as individual results may vary.
Slide 29: Patient Results At Baseline & Weeks Post Treatment
29 | © 2025 Journey Medical Corporation. All rights reserved. Patient Results At Baseline & 16 Weeks Post Treatment Actual patient images from Emrosi Phase 3 Clinical Trials. Photos used with permission. Results of individual patients may not be typical, as individual results may vary.
Slide 30: Journey Will Quickly Grow HCP Adoption Through Educational and Promotional Programs
30 | © 2025 Journey Medical Corporation. All rights reserved. Journey Medical’s upcoming exhibit booth at AAD. AAD is the premier dermatology conference in the U.S. with nearly 20,000 attendees. Journey Will Quickly Grow HCP Adoption of Emrosi Through a Range of Educational and Promotional Programs
Slide 31: Speakers & Agenda
31 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Louis Donati Director of Market Access • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Market Opportunity • Commercial Strategy • Financial Update • Closing Remarks
Slide 32: Market Access is Focused on Commercial / Government & Medicare
32 | © 2025 Journey Medical Corporation. All rights reserved. Market Access is Focused on Commercial / Government (FEP/HIX) & Medicare Commercial, Gov’t & Medicare ~242M Lives U.S. Population ~345M Lives Commercial & Government (Commercial, Employer, Fed Prog, Federal Employees, HIX, Municipal Plan,
Slide 33: Market Access Timelines
33 | © 2025 Journey Medical Corporation. All rights reserved. Jan Dec Nov Oct Sept Aug July June May April Mar Feb Jan Dec Nov APPROVAL TIMELINE PAYERS & ACCESS ACTIVITIES FDA APPROVAL LAUNCH Complete In Progress Payer Meetings - PVP, Clinical Deck, initial business discussions 2024 2025 2026 Clinic
Slide 34: Speakers & Agenda
34 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Joseph Benesch Chief Financial Officer • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Market Opportunity • Commercial Strategy • Market Access • Closing Remarks
Slide 35: Speakers & Agenda
35 | © 2025 Journey Medical Corporation. All rights reserved. Speakers & Agenda Claude Maraoui Founder, President & Chief Executive Officer • Commercial Highlights • Emrosi – Differentiated Clinical Profile • Market Opportunity • Commercial Strategy • Market Access • Financial Update
Slide 36: Journey Medical Corporation
J@URNEY MEDICAL CORPORATION O&A amzeeq (minocyeline) ‘topical foam, 4% Ee emrosi’ hydrochloride)